ATLAB announces winners of ‘FIRST® LEGO® League,' recognising UAE's young innovators in robotics
The FIRST® LEGO® League (FLL) 2024-25 season, hosted by ATLAB, a subsidiary of the Centena Group, in collaboration with FIRST® (For Inspiration and Recognition of Science and Technology) and LEGO® Education, announced the national winners from across the UAE during the grand finale of the 'CHALLENGE' category on February 9, 2025. The awards recognised young innovators from 42 participating teams for their exceptional creativity, problem-solving skills and teamwork in robotics and STEM.
The Champion's Winner Award was presented to Team 'ACE' from Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences, with Team 'PELAGIC PIONEERS' from DPS (Delhi Private School) – Sharjah as first runner-up and Team 'METAL MECH' from Gems International School – Al Khail as the second runner-up.
In the Robot Performance category, Team 'SEATROTTERS' from Gems Millenium School – Sharjah emerged as winners, followed by Team 'ACE' from Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences first runner-up and Team 'MARINE X' from Gems Millenium School Sharjah as the second runner-up.
The winners for Robot Design were Team 'AQUA RAPTORZ' from DPS – Sharjah, with Team 'SEATROTTERS' from Gems Millenium School – Sharjah as first runner-up and Team 'CODEBREAKERS 2.0' from Emerging Stars Institute as second runner-up.
The Innovation Project award went to Team 'MAWJ MYSTERY MASTERS (M CUBE)' from DPS – Sharjah, with Team 'HYDRATECH' from Mayoor Pvt School as first runner-up and Team 'NMS HYDROBOTS' from Gems New Millennium School – Al Khail as second runner-up.
Finally, the Core Values award was won by Team 'AIS_TECHTITANS' from Abu Dhabi International Pvt School, while Team 'ABYSSAL EXPLORERS' from Abu Dhabi Indian School secured first runner-up position and 'DIAEH TEAM 2' from Dubai International Academy – Emirates Hill secured the second runner-up position.
This year, the competition included the Motivate Award , which was presented to Team 'REEF RANGERS' from Diyar Private Academy Early Years and Girl's Campus Dibba, Fujairah in recognition of their exceptional team spirit, enthusiasm, and commitment to the core values of the FIRST® LEGO® League.
Charbel Najjar , the coach of Team ACE from Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences said : ' The competition provided us with a dynamic platform to exhibit our innovative concepts and gain valuable experience in the realms of problem-solving, teamwork, and STEM-related skills. We aim to carry this experience forward and continue to participate in similar competitions .'
The winners in the CHALLENGE category were assessed on the basis of their robot design, performance, innovation projects and core values. Team ACE that received the Champion's Winner Award are qualified for the international-level competition, which is held in the USA at the World Festival – Houston, Texas. Apart from this, selected teams will compete in the international competitions across the world; AIS_TECHTITANS from Abu Dhabi International Pvt School in Greece, SEATROTTERS from Gems Millenium School – Sharjah in South Africa, AQUA RAPTORZ from DPS – Sharjah and METAL MECH from Gems International School- Al Khail in Australia and PELAGIC PIONEERS from DPS – Sharjah in USA.
Nilesh Korgaonkar, CEO of ATLAB said: 'The exceptional projects created by these innovators may not be directly implemented, but they might inspire real-world solutions at an international level or adopted by organisations or countries associated with FIRST®. This competition is a platform for students to showcase their creativity, gain valuable experience and contribute to solving real-world problems. We are immensely proud of all the participants and winners who seized this opportunity. To ensure high-quality evaluation, we meticulously selected judges with expertise in STEM education and robotics.'
The teams were judged by esteemed professionals from different backgrounds, representing institutions, universities and schools across the UAE from both governmental and private organisations. This year's grand finale was further enriched by the presence of special guest Rasna Hussain, a CCDI Teacher and Trainer at the UAE's Ministry of Education, whose expertise spans Robotics, STEM Training, artificial intelligence (AI) and Machine Learning.
In line with the UAE's vision to foster a knowledge-based economy and empower future generations, initiatives like the FIRST® LEGO® League play a vital role in nurturing young innovators. By providing a platform to showcase creativity, problem-solving, and teamwork, ATLAB reaffirms its commitment to supporting the nation's aspirations for innovation and excellence in STEM fields.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
4 days ago
- Web Release
Hamdan Foundation Advances to Judging Stage of 2025 Medical Awards After Screening 330 Submissions
Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences has announced the completion of the screening process for the 2025 Medical Awards, which aim to recognize outstanding achievements in healthcare at both the local and regional levels. According to the awards committee, this year's cycle received a total of 330 submissions from 18 countries, including the United Arab Emirates, Saudi Arabia, Lebanon, Egypt, Oman, Iraq, India, Kuwait, the United Kingdom, Qatar, Jordan, the Democratic Republic of the Congo, Morocco, the United States, Pakistan, Tunisia, Syria, and Ghana. Following an initial review, 261 submissions advanced to the administrative and technical screening stage, which involved verifying compliance with the award's eligibility criteria and guidelines. Of those, 161 applications were confirmed as eligible and are now set to proceed to the judging phase, scheduled to begin on 2 June and continue until 15 October. The judging process will be carried out by specialized committees comprising distinguished experts in the field. Each submission will be assessed according to the specific evaluation criteria established for each award category. Dr. Salama Al Muhairi, Director of Medical Excellence at Hamdan Bin Rashid Al Maktoum Foundation, emphasized the significance of this stage, noting that the evaluation and screening of submissions adhere to the highest standards to ensure transparency and fairness throughout the process. She added that these efforts reflect the merit and credibility of the Medical Excellence Awards, which seek to spotlight innovations and achievements that contribute to the advancement of medical practices. The awards also aim to encourage and support researchers in producing impactful and innovative studies in medicine and healthcare. The Foundation is committed to sharing the benefits of award-winning work, offering it as a source of inspiration and a model for excellence in scientific and medical fields. These achievements also contribute to the development of new solutions to address growing challenges in the healthcare sector. The Medical Excellence Awards consist of two main categories. The first is dedicated to supporting health and research achievements across the Arab world and includes the Arab Award for Health Sector Research and the Arab Award for Genetic Sciences. The second category focuses on recognizing exceptional contributions within the United Arab Emirates and includes the Best Research in Healthcare Award, the Innovation in Healthcare Award, and the Hamdan Award for Distinguished Personalities. Over previous cycles, the awards have garnered wide recognition and attracted high-quality submissions from both inside and outside the UAE. This success reflects the Foundation's commitment to supporting innovation and fostering a culture of excellence in the healthcare sector, while highlighting major accomplishments in scientific research and healthcare delivery.
Al Etihad
5 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
Arabian Post
19-05-2025
- Arabian Post
LiveSpo® NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3–7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future. The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems. In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear's natural defense barrier. This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children. Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared: 'At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community – all with a vision of A Future Without Antibiotics.' References: Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584. Hashtag: #LiveSpo The issuer is solely responsible for the content of this announcement. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for 'A Future Without Antibiotics'. Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores – Spobiotic – will pave the way to a future without antibiotics for everyone. Hotline: 1800.088808 Website:
